Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous tumor cells/bacillus Calmette-Guérin/formalin-based vaccine

A therapeutic personalized breast cancer vaccine composed of autologous tumor cells and bacillus Calmette-Guerin (BCG) in a liquid vehicle containing formalin, with potential immunomodulating and antineoplastic activities. Upon vaccination, the autologous tumor cells/BCG/formalin-based vaccine, which contains an individual’s unique set of tumor-associated antigens (TAAs), may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against the breast cancer cells, resulting in decreased tumor growth. The BCG component serves as an adjuvant, a nonspecific stimulator of the immune response.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous tumor cells/BCG/formalin-based vaccine
US brand name:ConvitVax
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search